The Italian pharmaceutical company Doc, the second largest operator in the equivalent drugs market in our country, has announced that it has signed an agreement for the acquisition of Muscoril*, a drug with a muscle relaxant action, currently marketed by Sanofi, for Italy, Portugal and the Czech Republic. The operation, supported by the shareholders of Doc, Tpg and Icg – reports a note – will further enrich the company's offer and growth and lay the foundations for future expansion plans. Muscoril will strengthen Doc's existing product line, already packed with over 250 molecules in various therapeutic areas. The agreement is subject to customary closing conditions.
“The signing of this agreement – declares Riccardo Zagaria, CEO of Doc – represents an important step forward for Doc in our expansion path in the Italian market. Muscoril not only strengthens our current portfolio, but aligns perfectly with our growth strategy both both in the branded products market and in the equivalent medicines market. Operations like this allow us to build a solid and resilient platform, capable of supporting our future growth.” For Karthic Jayaraman, partner of Tpg, “the signing of the acquisition of Muscoril demonstrates DOC's ability to recognize valuable assets and create an integrated platform to improve care through access to essential, high-quality treatments. This operation will strengthen Doc's role as a reliable partner for doctors, pharmacists and patients. We are proud to support the company in its continued expansion.”
The agreement – details the note – provides for the transfer of brands, dossiers and marketing authorizations in Italy, Portugal and the Czech Republic. The acquisition does not include the transfer of production plants, as production will be managed on behalf of third parties. Thanks to its proven effectiveness, Muscoril has established itself as one of the leading brands among muscle relaxant drugs in Italy. The product is available in different pharmaceutical forms, including orodispersible tablets, capsules and injectable solutions, thus offering patients different treatment options. This strategic choice will further strengthen Doc's position on the market, confirming the company's commitment to improving health through effective and accessible treatments.
#Doc #acquires #Muscoril #Sanofi #agreement #signed
